Advances in the Classification and Treatment of Osteogenesis Imperfecta (Q38727952)

5 September 2017

1 reference

title

Advances in the Classification and Treatment of Osteogenesis Imperfecta (English)

1 reference

5 September 2017

osteogenesis imperfecta

0 references

2

Linda A DiMeglio

1 reference

5 September 2017

Inas H Thomas

1

1 reference

5 September 2017

9 February 2016

1 reference

Current osteoporosis reports

5 September 2017

1 reference

5 September 2017

14

1 reference

5 September 2017

1

1 reference

5 September 2017

1-9

1 reference

https://scigraph.springernature.com/pub.10.1007/s11914-016-0299-y

5 September 2017

0 references

cites work

Genetic heterogeneity in osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Nosology and classification of genetic skeletal disorders: 2010 revision.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Update on the evaluation and treatment of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Phenotypic variability of osteogenesis imperfecta type V caused by an IFITM5 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

New genes in bone development: what's new in osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Central corneal thickness is lower in osteogenesis imperfecta and negatively correlates with the presence of blue sclera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Novel quantitative trait loci for central corneal thickness identified by candidate gene analysis of osteogenesis imperfecta genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Evaluation of oral problems in an osteogenesis imperfecta population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Otopathology in Osteogenesis Imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

How common is hearing impairment in osteogenesis imperfecta?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Valvular heart disease in osteogenesis imperfecta: presentation of a case and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Rib cage deformities alter respiratory muscle action and chest wall function in patients with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Craniocervical abnormalities in osteogenesis imperfecta: genetic and molecular correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Basilar impression and osteogenesis imperfecta: a 21-year retrospective review of outcomes in 20 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Osteogenesis imperfecta: A clinical study of the first ten years of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Mutations in PLOD2 cause autosomal-recessive connective tissue disorders within the Bruck syndrome--osteogenesis imperfecta phenotypic spectrum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Cole-Carpenter syndrome is caused by a heterozygous missense mutation in P4HB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Mutations in SEC24D, encoding a component of the COPII machinery, cause a syndromic form of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Molecular basis for the progeroid variant of Ehlers-Danlos syndrome. Identification and characterization of two mutations in galactosyltransferase I gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Fractures at diagnosis in infants and children with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Osteoprotegerin deficiency and juvenile Paget's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Evaluation of teriparatide treatment in adults with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-016-0299-Y

Analysis of skeletal dysplasias in the Utah population

21 January 2018

1 reference

12 December 2020

Hypophosphatasia: an overview of the disease and its treatment

1 reference

12 December 2020

The mechanical properties of skin in osteogenesis imperfecta

1 reference

12 December 2020

Bisphosphonate therapy for osteogenesis imperfecta

1 reference

12 December 2020

First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI

1 reference

12 December 2020

Acute phase response and mineral status following low dose intravenous zoledronic acid in children

1 reference

12 December 2020

GH in combination with bisphosphonate treatment in osteogenesis imperfecta

1 reference

12 December 2020

Wormian bones in osteogenesis imperfecta: Correlation to clinical findings and genotype

1 reference

12 December 2020

10.1007/S11914-016-0299-Y

Identifiers

DOI

1 reference

PubMed ID

26861807

Dimensions Publication ID

5 September 2017

0 references

1 reference

PubMed ID

26861807